ライフサイエンスコーパス: intravaginally

1 n sacral ganglia from guinea pigs vaccinated intravaginally.

2 On day 17 of gestation mice received LPS intravaginally (10 to 240 mug; n = 3 to 8) or into the u

3 fected with HSV-2 intravaginally and treated intravaginally 24 h later with 100 microg DNA encoding I

4 Here we show that intravaginally administered interleukin 12 (IL-12) encap

5 tics of virus spread, we inoculated macaques intravaginally and euthanized them after 2, 4, 7, and 15

6 Mice infected with HSV-2 intravaginally and treated intravaginally 24 h later wit

7 intravenously or mucosally (intranasally or intravaginally) and then challenged intravaginally with

8 ted onto the cornea, intramuscularly (i.m.), intravaginally, and intracranially.

9 as shown promise as antiherpetics, including intravaginally applied CpG-containing oligodeoxynucleoti

10 However, when SEVI is intravaginally applied to living animals, there is no ef

11 We demonstrate that ZOTEN, when used intravaginally as a microbicide, is an effective suppres

12 cells, was detected in all hCD4/R5/cT1 mice intravaginally challenged with an HIV-1 infectious molec

13 ive groups of guinea pigs were immunized and intravaginally challenged with HSV-2.

14 Naive mice given the antiserum intravaginally developed 79% fewer fungal colony-forming

15 eic dendritic cells did not induce responses intravaginally even in ovariectomized mice in the absenc

16 r of the genital tract, rhesus macaques were intravaginally exposed to cell-free simian immunodeficie

17 Female BALB/c mice were infected intravaginally (i.v.), intranasally (i.n.), orally (p.o.

18 onses were compared in female mice immunized intravaginally (i.vag.) or intranasally (i.n.) with a ba

19 , BALB/c or congenic SCID mice were infected intravaginally (i.vag.) with the HSV type 2 (HSV-2) vhs

20 to either peptide Ag or male cells delivered intravaginally in ovariectomized mice, but this response

21 itope (gB(498-505)), and both were delivered intravaginally in the progesterone-induced B6 mouse mode

22 In intravaginally infected guinea pigs, HSV2-LAT-E1 reactiv

23 amydia-infected mice, and in initial studies intravaginally infected wild-type, IL-10(-/-), IL-4(-/-)

24 In the current study, 27 of 40 mice intravaginally infected with Chlamydia muridarum develop

25 rol of a CD4 promoter (JR-CSF/hu-cycT1) were intravaginally infected with HSV-2 and evaluated for dis

26 Guinea pigs were intravaginally infected with HSV-2 and then were randomi

27 The CBA/J mice intravaginally infected with the same plasmid-free C. mu

28 Intravaginally inoculated animals died within 6 months,

29 ravenous inoculation and a week later in the intravaginally inoculated animals.

30 ) T cells followed by development of AIDS in intravaginally inoculated macaques and thus provides a h

31 tics of retroviral recombination in vivo, we intravaginally inoculated rhesus macaques, either simult

32 e with pathogenic SIV, all five animals were intravaginally inoculated twice with pathogenic SIV-mac2

33 (-/-), IL-17RA(-/-) and IL-22(-/-) mice were intravaginally inoculated with Candida, and vaginal lava

34 was eventually found in four of six animals intravaginally inoculated with the two SIVmac239 deletio

35 1 (HIV-1) env/rev and gag/pol were delivered intravaginally (IVAG) and intramuscularly (IM) to 2 preg

36 while two additional adult female AGMs were intravaginally (IVAG) exposed.

37 us macaques inoculated intravenously (IV) or intravaginally (IVAG) with a genetically heterogeneous S

38 arious mucosal routes-oral, intrarectal, and intravaginally (ivag)-followed by a systemic or mucosal

39 Pregnant BALB/c mice were inoculated intravaginally on day 5 of gestation with the Chlamydia

40 sis of tissues of rhesus macaques inoculated intravaginally or i.v. with SIV supports the proposed ro

41 ce were inoculated with these strains either intravaginally or transcervically.

42 HeJ mice were either sham or INP0341 treated intravaginally pre- and postinoculation with 5 x 10(2) i

43 l mucosa, while the same antibodies injected intravaginally significantly reduced Thy-1+ T cells in b

44 in which female rhesus macaques were exposed intravaginally to a high dose of simian immunodeficiency

45 When applied intravaginally to humanized mice, CD4-AsiCs protected ag

46 re significantly greater in macaques exposed intravaginally to lower rather than higher inoculum dose

47 10(6)- or 10(8)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days.

48 served only in macaques that were challenged intravaginally twice within the same day with a high dos

49 Groups of guinea pigs were infected intravaginally with 10(4), 10(3), 10(2), and 10(1) inclu

50 nnate immunity-deficient C3H/HeJ female mice intravaginally with a human serovar D urogenital isolate

51 Mice inoculated intravaginally with a lethal dose of HSV-2, and treated

52 lowing immunization, animals were challenged intravaginally with C. muridarum.

53 emale C3H/HeN and C57BL/6 mice were infected intravaginally with Chlamydia muridarum.

54 into syngeneic naive animals and challenged intravaginally with Chlamydia, recipients of IM immuniza

55 mia, nonobese diabetic (NOD) mice inoculated intravaginally with clinical C. glabrata isolates were s

56 g from 5 to 14 weeks of age, were inoculated intravaginally with different doses of the Chlamydia tra

57 Chlamydia trachomatis, mice were challenged intravaginally with either MoPn or human serovar E or L2

58 t this hypothesis, we treated rhesus monkeys intravaginally with either the TLR9 agonist, CpG oligode

59 2Rgamma(-/-)) (NSG)-BLT mice were inoculated intravaginally with HIV and were monitored for plasma vi

60 or the licensed HPV vaccines and challenged intravaginally with HPV6, HPV16, HPV26, HPV31, HPV33, HP

61 O 2000 gel protected 100% of mice challenged intravaginally with HSV-2 introduced in PBS, whereas onl

62 vaccine FENDrix) and subsequently challenged intravaginally with HSV-2 or HSV-1.

63 a pigs immunized and subsequently challenged intravaginally with HSV-2.

64 e mice were immunized either intranasally or intravaginally with live elementary bodies (EB).

65 rogesterone or estradiol and then inoculated intravaginally with M. genitalium type strain G37 or a c

66 Macaques challenged intravaginally with pathogenic simian immunodeficiency v

67 sally or intravaginally) and then challenged intravaginally with pathogenic SIVmac239.

68 ult female macaques that had been inoculated intravaginally with pathogenic SIVmac251 became transien

69 PGT121 to rhesus monkeys and challenged them intravaginally with SHIV-SF162P3.

70 (controls; n = 7) were repeatedly challenged intravaginally with SHIVSF162p3.

71 ciency virus (SHIV) 89.6 and then challenged intravaginally with SIVmac239 controlled viral replicati

72 Four female rhesus macaques were inoculated intravaginally with SIVmac251, and then killed 2, 5, 7,

73 e TNF-alpha response in guinea pigs infected intravaginally with the guinea pig strain of Chlamydia p

74 feron gamma gene-deficient C57 mice infected intravaginally with the mouse pneumonitis agent of Chlam

75 A susceptible strain of mice infected intravaginally with the mouse pneumonitis biovar of Chla

76 L/6), treated with progesterone and infected intravaginally with the mouse pneumonitis strain of Chla

77 oth B7-1 and B7-2 (B7KO mice), when infected intravaginally with virulent herpes simplex virus type 2

78 B7KO mice infected intravaginally with virulent HSV-2 showed more severe ge

79 reated with 17-beta-estradiol and inoculated intravaginally with wild-type gonococcal strain FA1090 o

80 ceptibility to N. gonorrhoeae and inoculated intravaginally with wild-type gonococci or a catalase (k

81 asma vRNA levels seen for monkeys inoculated intravaginally with wt SIVmac239.

82 highly attenuated in wild-type mice infected intravaginally, with reduced mucosal replication, diseas